Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 325

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 325
---
 dividing the net loss by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the Company has reported net losses for each period presented. Note 3-Liquidityand management’s plans The Company has been engaged in research and development activities related to ImmuneFx, the Company’s patented product, which will require additional investment until revenue-generating activities can begin. The Company has historically incurred negative cash flows from operations. For the year ended December 31, 2024, the Company incurred $ 14.7million of negative cash flows from operations. The Company has approximately $ 12.7million of cash and cash equivalents on hand at December 31, 2024. The Company expects that its existing capital resources, including anticipated payment of the Warrant Exercise Notes (as defined and described in Note 15 below), will be sufficient to fund the Company’s planned future operations into the late fourth quarter of 2025. F-8 1

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023 The Company expects to raise cash through the sale of preferred shares, common shares, debt issuances, obtaining grants, or commercial partnerships. However, there can be no assurance that any fundraising will be achieved or on commercially reasonable terms, if at all. As such, there is substantial doubt about the Company’s ability to continue as a going concern for the next 12 months from date that the financial statements were available to be issued.

Note 4-Netloss per share

Basic and diluted net loss per share attributable to common stockholders was calculated as follows:

| Numerator:                                                                 |     | Years Ended December 31, 
 2024                     |             |   |     | 2023 |             |   |
|:---------------------------------------------------------------------------|:----|:-------------------------|------------:|:--|:----|:-----|------------:|:--|
| Net loss attributable to common stockholders                               |     | $                        | (22,649,572 | ) |     | $    | (29,316,826 | ) |
| Denominator:                                                               |     |                          |             |   |     |      |             |   |
| Weighted-average common shares outstanding -